Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CTSV | O60911 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | PPIA | P62937 | 3/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PPIF | P30405 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15942070 | 0.87 | CYP19A1 (0.65) | CYP19A1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL6567396 | 0.87 | MEN1 (0.64) | CYP19A1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL7663256 | 0.85 | RAB9A (0.54) | CYP19A1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL12114840 | 0.85 | RORC (0.54) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL7900646 | 0.81 | MAOB (0.55) | CYP19A1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL9068677 | 0.80 | ALDH1A1 (0.54) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL13011586 | 0.80 | KMT2A (0.54) | CYP19A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL14744562 | 0.80 | AKR1C3 (0.44) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL20695012 | 0.80 | RAB9A (0.60) | CYP19A1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL27946684 | 0.79 | CYP19A1 (0.58) | CYP19A1MEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1944290-B1 | NOVEL 1-2-DIHYDROQUINOLINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-8420635-B2 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8420635-B2 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8420635-B2 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| CN-102311385-A | Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO LTD | 2012-01-11 | — | — | CN | disclosed |
| CN-102304124-A | Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO LTD | 2012-01-04 | — | — | CN | disclosed |
| CN-102229562-A | Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO LTD | 2011-11-02 | — | — | CN | disclosed |
| US-20110263589-A1 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263589-A1 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263589-A1 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-8017775-B2 | 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-8017775-B2 | 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-8017775-B2 | 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20090326009-A1 | Novel 1-2-Dihydroquinoline Derivative Having Glucocorticoid Receptor Binding Activity | Santen Pharmaceutical Co., (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090326009-A1 | Novel 1-2-Dihydroquinoline Derivative Having Glucocorticoid Receptor Binding Activity | Santen Pharmaceutical Co., (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090326009-A1 | Novel 1-2-Dihydroquinoline Derivative Having Glucocorticoid Receptor Binding Activity | Santen Pharmaceutical Co., (JP) | 2009-12-31 | — | — | US | disclosed |
| CN-101263119-A | Novel 1, 2-dihydroquinoline derivatives having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO LTD (JP) | 2008-09-10 | — | — | CN | disclosed |
| EP-1944290-A1 | NOVEL 1-2-DIHYDROQUINOLINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1944290-A1 | NOVEL 1-2-DIHYDROQUINOLINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326009-A1 | Novel 1-2-Dihydroquinoline Derivative Having Glucocorticoid Receptor Binding Activity | NR3C1, NR3C2, NR5A1 | CYP19A1 690/4885MEN1 3827/4885KMT2A 3137/4885 |
| US-20110263589-A1 | Method for preventing or treating a glucocorticoid receptor-related disease | NR3C1, NR3C2, NR5A1 | CYP19A1 565/4885MEN1 1768/4885KMT2A 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.